Home - Syndax

Determined to realize a future in which people with cancer live longer and better than ever before.

07.10.19

Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

06.13.19

Syndax to Present at the JMP Securities Life Sciences Conference

05.14.19

Syndax to Present at the UBS Global Healthcare Conference

05.06.19

Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update